Pharmacokinetic Determinants of Ponatinib‐Induced Vascular Toxicity: A Possible Role of Perivascular Adipose Tissue
Basic & Clinical Pharmacology & Toxicology · 2026
DOI: 10.1111/bcpt.70181 ↗Kurz gefasst
Fachartikel in der Zeitschrift Basic & Clinical Pharmacology & Toxicology, 2026. Verfasst von Iwaine Benbouziane und 9 weiteren Autor:innen. Beteiligte Einrichtung: Jagiellonian Centre for Experimental Therapeutics (JCET), Jagiellonian University, Krakow, Poland. Hauptthemen laut MEDLINE: Imidazoles, Pyridazines, Adipose Tissue, Protein Kinase Inhibitors. Die Arbeit nennt 84 Literaturangaben. Gefördert von: European Regional Development Fund.
Abstract (Originalsprache)
Tyrosine kinase inhibitors (TKIs) have revolutionised chronic myeloid leukaemia treatment but cause cardiovascular toxicities through incompletely understood mechanisms. This study characterised the pharmacokinetics of imatinib, nilotinib and ponatinib, focusing on perivascular adipose tissue (PVAT) accumulation and vascular toxicity in C57BL/6 mice. Ponatinib showed unique pharmacokinetics with high apparent mean residence time (5.22 h vs. 1.51 h for imatinib, and 3.20 h for nilotinib) and high apparent distribution volume (2891.33 mL/kg vs. 683.75 mL/kg for imatinib, and 74.84 mL/kg for nilotinib). Importantly, ponatinib had exceptionally high tissue‐to‐plasma ratio in aorta with PVAT (8.44 vs. 0.37 for imatinib, and 0.14 for nilotinib). Chronic ponatinib treatment (10 mg/kg, 4 weeks) severely impaired endothelium‐dependent vasodilation assessed by magnetic resonance imaging in vivo (thoracic aorta −7.4 ± 1.1% vs. controls 5.1 ± 1.3%). Ponatinib accumulated in aorta with PVAT after chronic treatment and directly impaired adipocyte maturation in in vitro experiments. In isolated aorta, ponatinib reduced vascular nitric oxide (NO) release. In conclusion, endothelial dysfunction and impaired NO‐dependent function induced by ponatinib were related to a unique profile of ponatinib distribution compared with other TKIs, along with direct effects on adipocyte maturation. Our results suggest that after chronic treatment, ponatinib accumulation in PVAT leads to the impairment of the vasoprotective function of PVAT, contributing to endothelial dysfunction induced by ponatinib.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Jagiellonian Centre for Experimental Therapeutics (JCET), Jagiellonian University, Krakow, Poland.
- Doctoral School of Exact and Natural Sciences, Jagiellonian University, Krakow, Poland.
- Department of Pharmacology, Jagiellonian University Medical College, Krakow, Poland.
ORCID-Profile: Krzysztof Czamara, Anna Gdula, Agnieszka Karas, Stefan Chlopicki
Förderung
- European Regional Development Fund
Zitieren
APA
Benbouziane, I., Marczyk, B., Czamara, K., Kurylowicz, Z., Buczek, E., Gdula, A., Karas, A., Bar, A., Kij, A., & Chlopicki, S. (2026). Pharmacokinetic Determinants of Ponatinib‐Induced Vascular Toxicity: A Possible Role of Perivascular Adipose Tissue. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/bcpt.70181
Vancouver
Benbouziane I, Marczyk B, Czamara K, Kurylowicz Z, Buczek E, Gdula A, et al. Pharmacokinetic Determinants of Ponatinib‐Induced Vascular Toxicity: A Possible Role of Perivascular Adipose Tissue. Basic & Clinical Pharmacology & Toxicology. 2026. doi:10.1111/bcpt.70181
BibTeX
@article{Benbouziane2026,
author = {Benbouziane, Iwaine and Marczyk, Brygida and Czamara, Krzysztof and Kurylowicz, Zuzanna and Buczek, Elzbieta and Gdula, Anna and Karas, Agnieszka and Bar, Anna and Kij, Agnieszka and Chlopicki, Stefan},
title = {Pharmacokinetic Determinants of Ponatinib‐Induced Vascular Toxicity: A Possible Role of Perivascular Adipose Tissue},
journal = {Basic & Clinical Pharmacology & Toxicology},
year = {2026},
doi = {10.1111/bcpt.70181}
}
EUVIMED